Taizou Hirano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Taizou Hirano has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Masakazu Ichinose
Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
4 shared publications Hajime Kurosawa
Department of Occupational Health, Tohoku University Graduate School of Medicine, Japan
3 shared publicationsHisatoshi Sugiura
Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Japan
3 shared publications- Hisatoshi Sugiura
Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan
3 shared publications - Akira Koarai
Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
2 shared publications - Kazuhiro Sakamoto
Department of Pathology, Osaki Citizen Hospital, Osaki 989-6183, Japan
2 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Low AHI with elevated T90 as a clinical clue to underlying respiratory impairment in the sleep heart health study
Extract The apnoea–hypopnoea index (AHI) remains the dominant metric for classifying sleep-disordered breathing severity, but it captures event frequency, not the depth, duration, or cumulative burden of nocturnal oxygen desaturation. Oxygenation-based metrics, including T90 (percentage of sleep time with SpO2 <90%) and sleep apnoea-specific hypoxic burden, provide cardiopulmonary prognostic information beyond AHI [1–3], suggesting that nocturnal hypoxaemia captures dimensions not reflected by AHI.
- 15 October 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Open AccessLow AHI with elevated T90 as a clinical clue to underlying respiratory impairment in the sleep heart health study
Extract The apnoea–hypopnoea index (AHI) remains the dominant metric for classifying sleep-disordered breathing severity, but it captures event frequency, not the depth, duration, or cumulative burden of nocturnal oxygen desaturation. Oxygenation-based metrics, including T90 (percentage of sleep time with SpO2 <90%) and sleep apnoea-specific hypoxic burden, provide cardiopulmonary prognostic information beyond AHI [1–3], suggesting that nocturnal hypoxaemia captures dimensions not reflected by AHI.
- Open Access
- 9 November 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (2)
Keratin-5-positive basal-like epithelial cells associate with forced vital capacity in idiopathic pulmonary fibrosis; a cross-sectional analysis
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease characterised by irreversible loss of lung function from fibrosis and alveolar remodelling. Although antifibrotic therapies have improved outcomes, disease progression remains variable and poorly understood [1]. Recent studies have identified aberrant epithelial remodelling – including expansion of basal-like keratin-5 (KRT5)-positive cells – as a feature of IPF [2, 3]. These cells, typically absent from healthy distal lung, emerge in fibrotic regions in a process termed “bronchiolisation”, where distal alveolar epithelium acquires airway-like features [3–5].
- 9 November 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (2)
Open AccessKeratin-5-positive basal-like epithelial cells associate with forced vital capacity in idiopathic pulmonary fibrosis; a cross-sectional analysis
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease characterised by irreversible loss of lung function from fibrosis and alveolar remodelling. Although antifibrotic therapies have improved outcomes, disease progression remains variable and poorly understood [1]. Recent studies have identified aberrant epithelial remodelling – including expansion of basal-like keratin-5 (KRT5)-positive cells – as a feature of IPF [2, 3]. These cells, typically absent from healthy distal lung, emerge in fibrotic regions in a process termed “bronchiolisation”, where distal alveolar epithelium acquires airway-like features [3–5].
- Open Access
- 20 May 2025
- Published by Springer Nature in Cureus
- Vol. 17 (5) , e84488
Low Secretory Leukocyte Protease Inhibitor (SLPI)-Level Potentiates Alternaria Extract-Induced T-Helper 2 (Th2) Airway Inflammation via the Interleukin-33 (IL-33) Pathway
Introduction Serine proteases play a critical role in the augmented release and cleavage of IL-33, leading to the expansion of group 2 innate lymphoid cells (ILC2s) and T-helper 2 (Th2) airway inflammation. However, the protective regulation of protease-dependent interleukin-33 (IL-33) activation remains poorly understood. Therefore, we investigated the role of secretory leukocyte protease inhibitor (SLPI), as a serine protease inhibitor, in this protective regulation and aimed to clarify its contribution to type 2 immunity. Methods We evaluated the role of SLPI in the Alternaria extract-induced expansion of ILC2s and Th2-type airway inflammation via IL-33, using three models: SLPI-deficient mice, an in vivo SLPI knockdown model with shRNA, and an in vitro model utilizing primary human bronchial epithelial cells (HBECs) exposed to Alternaria extract under various conditions, including plasmid transfection. Results We showed that two mouse models of downregulation of SLPI gene expression augmented Alternaria extract-induced release of IL-33 and the expansion of ILC2s, together with Th2 airway inflammation. Furthermore, two treatment models using SLPI KO mice, administration of a serine protease inhibitor, bovine pancreatic trypsin inhibitor, or anti-IL-33 antibody, attenuated Th2 airway inflammation. In two in vitro experiments, SLPI, as a serine protease inhibitor, prevented both the release of IL-33 from HBECs and the cleavage of full-length IL-33 to shorter mature forms by neutrophil elastase. Discussion These findings suggest that SLPI functions as a key serine protease inhibitor in regulating IL-33-mediated type 2 immune responses. Low SLPI levels may contribute to the pathogenesis of asthma by promoting Th2 inflammation, highlighting SLPI as a potential therapeutic target in patients with low SLPI expression.
- 20 May 2025
- Published by Springer Nature in Cureus
- Vol. 17 (5) , e84488
Open AccessLow Secretory Leukocyte Protease Inhibitor (SLPI)-Level Potentiates Alternaria Extract-Induced T-Helper 2 (Th2) Airway Inflammation via the Interleukin-33 (IL-33) Pathway
Introduction Serine proteases play a critical role in the augmented release and cleavage of IL-33, leading to the expansion of group 2 innate lymphoid cells (ILC2s) and T-helper 2 (Th2) airway inflammation. However, the protective regulation of protease-dependent interleukin-33 (IL-33) activation remains poorly understood. Therefore, we investigated the role of secretory leukocyte protease inhibitor (SLPI), as a serine protease inhibitor, in this protective regulation and aimed to clarify its contribution to type 2 immunity. Methods We evaluated the role of SLPI in the Alternaria extract-induced expansion of ILC2s and Th2-type airway inflammation via IL-33, using three models: SLPI-deficient mice, an in vivo SLPI knockdown model with shRNA, and an in vitro model utilizing primary human bronchial epithelial cells (HBECs) exposed to Alternaria extract under various conditions, including plasmid transfection. Results We showed that two mouse models of downregulation of SLPI gene expression augmented Alternaria extract-induced release of IL-33 and the expansion of ILC2s, together with Th2 airway inflammation. Furthermore, two treatment models using SLPI KO mice, administration of a serine protease inhibitor, bovine pancreatic trypsin inhibitor, or anti-IL-33 antibody, attenuated Th2 airway inflammation. In two in vitro experiments, SLPI, as a serine protease inhibitor, prevented both the release of IL-33 from HBECs and the cleavage of full-length IL-33 to shorter mature forms by neutrophil elastase. Discussion These findings suggest that SLPI functions as a key serine protease inhibitor in regulating IL-33-mediated type 2 immune responses. Low SLPI levels may contribute to the pathogenesis of asthma by promoting Th2 inflammation, highlighting SLPI as a potential therapeutic target in patients with low SLPI expression.
- Open Access
- 29 January 2020
- Published by Springer Nature in BMC Rheumatology
- Vol. 4 (1) , 1-6
A case of localized tracheobronchial relapsing polychondritis with positive matrilin-1 staining
Background: Relapsing polychondritis (RPC) is a rare progressive autoimmune disease characterized by inflammation in the cartilage of multiple organs. Tracheobronchial involvement appears in nearly half of RPC patients during the course of their disease and represents the main cause of death. Localized tracheobronchial RPC is much rarer, and the pathogenesis remains unclear. Matrilin-1 is a non-collagenous cartilage matrix protein and has been suggested to be a potent autoantigen that induces the airway disease of RPC in animal models. However, the expression of matrilin-1 in tracheobronchial tissue in human remains unclear. Therefore, we examined the expression of matrilin-1 in the tracheal and auricular tissues in a localized tracheobronchial RPC patient. Case presentation: A 62-year-old man with systemic sclerosis presented with cough and dyspnea on exertion. The lung function test showed an expiratory flow limitation and chest computed tomography showed diffuse thickness from the trachea to the bronchiole. No other tests showed abnormal findings. To evaluate further, bronchoscopy was performed and endobronchial ultrasonography showed thickness in the fourth-marginal echo layer suggesting inflammation of the cartilage. However, the tracheal biopsy showed no specific findings. The subsequent surgical tracheal biopsies showed inflammatory cell infiltration with destruction of the cartilage. Neither auricular nor nasal deformity, except for a tracheobronchial lesion, was detected. Biopsy from the left auricular cartilage also did not show any inflammatory changes. Finally, we diagnosed the patient with localized tracheobronchial RPC. To address the hypothesis that autoimmunity against matrilin-1 is involved in the pathogenesis of localized tracheobronchial RPC, we evaluated the expression level of matrilin-1 in a tracheal and auricular specimen from this patient. Immunohistochemical staining with anti-matrilin-1 antibody showed matrilin-1 in the tracheal but not in the auricular cartilage. Conclusions: We first demonstrated the expression of matrilin-1 in tracheal but not in auricular cartilage in a localized tracheobronchial RPC patient. This result supports the possibility that matrilin-1 is involved in the pathogenesis of localized tracheobronchial RPC. However, this is only one case report and further observations will be needed to confirm this result.
- 29 January 2020
- Published by Springer Nature in BMC Rheumatology
- Vol. 4 (1) , 1-6
Open AccessA case of localized tracheobronchial relapsing polychondritis with positive matrilin-1 staining
Background: Relapsing polychondritis (RPC) is a rare progressive autoimmune disease characterized by inflammation in the cartilage of multiple organs. Tracheobronchial involvement appears in nearly half of RPC patients during the course of their disease and represents the main cause of death. Localized tracheobronchial RPC is much rarer, and the pathogenesis remains unclear. Matrilin-1 is a non-collagenous cartilage matrix protein and has been suggested to be a potent autoantigen that induces the airway disease of RPC in animal models. However, the expression of matrilin-1 in tracheobronchial tissue in human remains unclear. Therefore, we examined the expression of matrilin-1 in the tracheal and auricular tissues in a localized tracheobronchial RPC patient. Case presentation: A 62-year-old man with systemic sclerosis presented with cough and dyspnea on exertion. The lung function test showed an expiratory flow limitation and chest computed tomography showed diffuse thickness from the trachea to the bronchiole. No other tests showed abnormal findings. To evaluate further, bronchoscopy was performed and endobronchial ultrasonography showed thickness in the fourth-marginal echo layer suggesting inflammation of the cartilage. However, the tracheal biopsy showed no specific findings. The subsequent surgical tracheal biopsies showed inflammatory cell infiltration with destruction of the cartilage. Neither auricular nor nasal deformity, except for a tracheobronchial lesion, was detected. Biopsy from the left auricular cartilage also did not show any inflammatory changes. Finally, we diagnosed the patient with localized tracheobronchial RPC. To address the hypothesis that autoimmunity against matrilin-1 is involved in the pathogenesis of localized tracheobronchial RPC, we evaluated the expression level of matrilin-1 in a tracheal and auricular specimen from this patient. Immunohistochemical staining with anti-matrilin-1 antibody showed matrilin-1 in the tracheal but not in the auricular cartilage. Conclusions: We first demonstrated the expression of matrilin-1 in tracheal but not in auricular cartilage in a localized tracheobronchial RPC patient. This result supports the possibility that matrilin-1 is involved in the pathogenesis of localized tracheobronchial RPC. However, this is only one case report and further observations will be needed to confirm this result.
- Open Access
- 19 October 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 995
Possible involvement of interleukin-18 in the pathology of hepatobiliary adverse effects related to treatment with ceritinib
Ceritinib demonstrated a statistically significant effect on the progression-free survival versus chemotherapy in patients with advanced anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) as the first therapy or after previous treatment with crizotinib and one or two prior chemotherapy regimens in global phase 3 studies. However, some serious adverse effects related to ceritinib therapy were reported across these clinical studies. Among them, a grade 3 and 4 increase in hepatobiliary enzymes was one of the common adverse events related to treatment with ceritinib. However, the pathology remains unclear. Previously, increased Interleukin (IL)-18 was observed in both biliary duct disease and liver disease. Therefore, we hypothesized that IL-18 is involved in the pathology of hepatobiliary adverse effects related to treatment with ceritinib and evaluated the serum IL-18. The patient was a 53-year-old Japanese woman that we previously reported as having severe hepatobiliary adverse effects related to ceritinib therapy. Laboratory data, CT and MRI were obtained at each time point. IL-18 was evaluated by ELISA method at each time point. Immunochemical staining of liver tissue was performed as a standard protocol using antibodies against IL-18. Our records showed that the levels of serum IL-18 increased from the early stage of hepatobiliary adverse effects related to the treatment with ceritinib and were became worse with an increase in hepatobiliary enzymes and the progression of imaging abnormalities in the bile duct. Furthermore, IL-18 positive cells were detected in the inflammatory sites around the interlobular bile duct of the liver tissue. Our case report shows that the increase of serum IL-18 had a positive correlation with the progression of severe hepatobiliary adverse effects related to treatment with ceritinib and the involvement of IL-18 in the hepatobiliary inflammation by pathological evaluation. These results suggest that IL-18 could be a useful surrogate marker for the hepatobiliary toxicity of ceritinib. However, this is only one case report and further prospective observations will complement our data in the future.
- 19 October 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 995
Open AccessPossible involvement of interleukin-18 in the pathology of hepatobiliary adverse effects related to treatment with ceritinib
Ceritinib demonstrated a statistically significant effect on the progression-free survival versus chemotherapy in patients with advanced anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) as the first therapy or after previous treatment with crizotinib and one or two prior chemotherapy regimens in global phase 3 studies. However, some serious adverse effects related to ceritinib therapy were reported across these clinical studies. Among them, a grade 3 and 4 increase in hepatobiliary enzymes was one of the common adverse events related to treatment with ceritinib. However, the pathology remains unclear. Previously, increased Interleukin (IL)-18 was observed in both biliary duct disease and liver disease. Therefore, we hypothesized that IL-18 is involved in the pathology of hepatobiliary adverse effects related to treatment with ceritinib and evaluated the serum IL-18. The patient was a 53-year-old Japanese woman that we previously reported as having severe hepatobiliary adverse effects related to ceritinib therapy. Laboratory data, CT and MRI were obtained at each time point. IL-18 was evaluated by ELISA method at each time point. Immunochemical staining of liver tissue was performed as a standard protocol using antibodies against IL-18. Our records showed that the levels of serum IL-18 increased from the early stage of hepatobiliary adverse effects related to the treatment with ceritinib and were became worse with an increase in hepatobiliary enzymes and the progression of imaging abnormalities in the bile duct. Furthermore, IL-18 positive cells were detected in the inflammatory sites around the interlobular bile duct of the liver tissue. Our case report shows that the increase of serum IL-18 had a positive correlation with the progression of severe hepatobiliary adverse effects related to treatment with ceritinib and the involvement of IL-18 in the hepatobiliary inflammation by pathological evaluation. These results suggest that IL-18 could be a useful surrogate marker for the hepatobiliary toxicity of ceritinib. However, this is only one case report and further prospective observations will complement our data in the future.
- 10 May 2017
- Published by Japanese Society of Internal Medicine in Nihon Naika Gakkai Zasshi
- Vol. 106 (5) , 1006-1011
A Case of Pulmonary Eosinophilia as a Rare Presentation of Pulmonary Mucormycosis
症例は74歳,男性.腹部大動脈破裂術後より発熱・呼吸苦が出現,院内肺炎を疑い,加療を行ったが改善を認めず,抗菌薬不応の肺炎の精査目的に気管支鏡検査を施行した.肺胞洗浄液中,好酸球の増加と糸状菌を認め,好酸球性肺炎と診断.しかし,さらなる加療に反応せず,第39病日に死亡.病理解剖にて侵襲性肺接合菌症の診断が確定した.稀ではあるが,侵襲性肺真菌症と真菌による肺アレルギー性疾患を同時発症することに留意する必要がある.
- 10 May 2017
- Published by Japanese Society of Internal Medicine in Nihon Naika Gakkai Zasshi
- Vol. 106 (5) , 1006-1011
A Case of Pulmonary Eosinophilia as a Rare Presentation of Pulmonary Mucormycosis
症例は74歳,男性.腹部大動脈破裂術後より発熱・呼吸苦が出現,院内肺炎を疑い,加療を行ったが改善を認めず,抗菌薬不応の肺炎の精査目的に気管支鏡検査を施行した.肺胞洗浄液中,好酸球の増加と糸状菌を認め,好酸球性肺炎と診断.しかし,さらなる加療に反応せず,第39病日に死亡.病理解剖にて侵襲性肺接合菌症の診断が確定した.稀ではあるが,侵襲性肺真菌症と真菌による肺アレルギー性疾患を同時発症することに留意する必要がある.
- 14 July 2016
- Published by Elsevier in Respiratory Investigation
- Vol. 54 (6) , 494-499
Two cases of pseudo-achalasia with lung cancer: Case report and short literature review
- 14 July 2016
- Published by Elsevier in Respiratory Investigation
- Vol. 54 (6) , 494-499
Two cases of pseudo-achalasia with lung cancer: Case report and short literature review
- 1 May 2016
- Published by Elsevier in Respiratory Investigation
- Vol. 54 (3) , 211-215
Two cases of endobronchial aspergilloma complicated with primary and metastatic lung cancer: A case report and literature review
- 1 May 2016
- Published by Elsevier in Respiratory Investigation
- Vol. 54 (3) , 211-215
Two cases of endobronchial aspergilloma complicated with primary and metastatic lung cancer: A case report and literature review